News & Updates

Nutrivigilance is the systematic monitoring, assessment, and prevention of adverse effects related to the use of food supplements, fortified foods, and other nutritional products. It is the pharmacovigilance equivalent for the nutraceutical and functional food sector.

This document is the "EDA Renal Anaemia Guidance to Good Pharmacy Practice" (Code: EDREX:GU.CAP.Care.016, Version: 2025), issued by the Egyptian Drug Authority's Central Administration of Pharmaceutical Care. It serves as a comprehensive, evidence-based clinical practice guideline for the management of anemia in patients with Chronic Kidney Disease (CKD).

The health-related SDGs are a subset of the United Nations’ 17 Sustainable Development Goals (2015–2030) that specifically focus on improving global health outcomes. They are tracked under SDG 3: “Ensure healthy lives and promote well-being for all at all ages”, but also include health-related indicators from other SDGs (e.g., clean water, nutrition, gender equality).

This is a master research protocol published by the World Health Organization (WHO) in 2025. Its primary purpose is to provide a standardized, ready-to-use blueprint for countries—particularly low- and middle-income countries (LMICs)

The UK Centre of Excellence for Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) has developed a landmark guideline on CYP2C19 genotype testing for clopidogrel, published in the British Journal of Clinical Pharmacology in 2025.

This document is the Report of the CIOMS Working Group XIV on Artificial Intelligence in Pharmacovigilance. It addresses the rapidly emerging and cross-disciplinary field of integrating Artificial Intelligence (AI) into Pharmacovigilance (PV).

This document is the official strategy published by the World Health Organization (WHO) to provide a practical and adaptable framework for countries, particularly Low- and Middle-Income Countries (LMICs), to build, strengthen, and sustain their Pharmacovigilance (PV) systems for medicines and vaccines.